Compare TPVG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | TNXP |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 199.7M |
| IPO Year | 2013 | 2008 |
| Metric | TPVG | TNXP |
|---|---|---|
| Price | $4.48 | $9.92 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.90 | N/A |
| AVG Volume (30 Days) | 257.3K | ★ 544.8K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $7.67 | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $4.41 | $10.03 |
| 52 Week High | $7.24 | $69.65 |
| Indicator | TPVG | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 35.99 |
| Support Level | N/A | N/A |
| Resistance Level | $5.70 | $13.18 |
| Average True Range (ATR) | 0.16 | 0.93 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 15.32 | 1.20 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.